Leukemia Research
Volume 30, Issue 12 , Pages 1499-1505 , December 2006

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-α-expressing cells

  • Srdan Verstovsek

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • Corresponding Author InformationCorresponding author at: UT MD Anderson Cancer Center, Department of Leukemia, Unit 428, PO Box 301402, Houston, TX 77230, United States. Tel.: +1 713 745 3429; fax: +1 713 794 4297.
    • ,
  • Francis J. Giles

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Alfonso Quintás-Cardama

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Taghi Manshouri

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Ly Huynh

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Paul Manley

      Affiliations

    • Novartis Institutes for Biomedical Research, Basel, Switzerland
    • ,
  • Jorge Cortes

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Ayalew Tefferi

      Affiliations

    • Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, United States
    • ,
  • Hagop Kantarjian

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States

Received 24 January 2006 ,Revised 13 March 2006 ,Accepted 14 March 2006.

References 

  1. Giles FJ, Cortes JE, Kantarjian HM. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr Mol Med. 2005;5:615–623
  2. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105:986–993
  3. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003;102:795–801
  4. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005;1754(1/2):3–13
  5. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505
  6. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11:4941–4947
  7. Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005;104:1230–1236
  8. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214
  9. Ault P, Cortes J, Koller C, et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881–884
  10. Cervetti G, Galimberti S, Carulli G, et al. Imatinib therapy in hypereosinophilic syndrome: a case of molecular remission. Leuk Res. 2005;29:1097–1098
  11. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714–4716
  12. Cools J, Quentmeier H, Huntly BJ, et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2004;103:2802–2805
  13. Hannah AL. Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med. 2005;5:625–642
  14. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141
  15. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005;106:3206–3213
  16. Kantarjian H, Ottomann O, Cortes J, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph+ ALL). Blood. 2005;106(11):(abstr. 37)
  17. Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol. 2002;117:360–367
  18. Bueso-Ramos CE, Cortes J, Talpaz M, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer. 2004;101:332–336
  19. Kimura A, Nakata Y, Hyodo H, et al. Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis. Br J Haematol. 1994;86:303–307
  20. Yang M, Khachigian LM, Hicks C, et al. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb Haemost. 1997;78:892–896
  21. Le Bousse-Kerdiles MC, Martyre MC. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin Immunopathol. 1999;21:491–508
  22. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist. 2001;6:233–238
  23. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3:459–469

PII: S0145-2126(06)00124-X

doi: 10.1016/j.leukres.2006.03.012

Leukemia Research
Volume 30, Issue 12 , Pages 1499-1505 , December 2006

Article Tools

* Image Usage & Resolution